Nucleic acids encoding antagonists of interleukin-15
AssigneeBeth Israel Deaconess Medical Center, Inc., a Massachusetts corporation
InventorsTerry Strom, Wlodzimierz Maslinski
Life of this patent
Estimating the term…
Abstract
Disclosure herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.
Claims28
1-18. (canceled)
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a mutant interleukin-15 (IL-15) polypeptide, wherein the mutant IL-15 polypeptide has a mutation at position 149 of SEQ ID NO:6 and inhibits at least one of the cellular events that normally occurs when wild-type IL-15 specifically binds to an IL-15 receptor complex.
20-36. (canceled)
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a chimeric polypeptide, the chimeric polypeptide comprising
- (a) a mutant IL-15 polypeptide that has mutations at positions 149 and 156 of SEQ ID NO:6 and inhibits at least one of the cellular events that normally occurs when wild-type IL-15 specifically binds to an IL-15 receptor complex;
- (b) a polypeptide that increases the circulating half-life of the mutant IL-15 polypeptide;
- and
- (c) optionally, a marker.
A nucleic acid molecule comprising the sequence of SEQ ID NO:7.
Dependencies are inferred from the claim text.